These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28429551)

  • 21. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
    Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
    Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease.
    Navaneethan SD; Sakhuja A; Arrigain S; Sharp J; Schold JD; Nally JV
    Clin Nephrol; 2014 Jul; 82(1):16-25. PubMed ID: 24887302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
    Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X
    Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphate management in chronic kidney disease.
    Bhan I
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non calcium phosphate binders - Is there any evidence of benefit.
    Jadav PR; Husain SA; Mohan S; Crew R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):288-296. PubMed ID: 35266882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal phosphate control: still an unmet need in chronic kidney disease patients.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2014 Feb; 15(3):307-9. PubMed ID: 24283572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.
    Locatelli F; Dimkovic N; Spasovski G
    Expert Opin Pharmacother; 2014 Jul; 15(10):1475-88. PubMed ID: 24914480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral phosphate binders.
    Hutchison AJ
    Kidney Int; 2009 May; 75(9):906-14. PubMed ID: 19279554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moderator's view: Phosphate binders in chronic kidney disease patients: a clear 'No' at the moment, but stay tuned.
    Zoccali C; Mallamaci F
    Nephrol Dial Transplant; 2016 Feb; 31(2):196-9. PubMed ID: 26681749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dietary calcium intake does not meet the nutritional requirements of children with chronic kidney disease and on dialysis.
    McAlister L; Silva S; Shaw V; Shroff R
    Pediatr Nephrol; 2020 Oct; 35(10):1915-1923. PubMed ID: 32385527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.